Getting Beyond the Ganglion Cell Morphometric Adjustments for Retinal Optical Coherence Tomography in Multiple Sclerosis

The treatment of relapsing multiple sclerosis (MS) remains a rare beacon of success in the long campaign against neurological disease. The ready availability of a phase II clinical outcome (eg, gadolinium-enhancing lesion) that tracks a relevant phase III clinical outcome (eg, annualized relapse rate) is one of the major reasons for this success. Eight therapies have been approved by the US Food and Drug Administration in less than 20 years, and 3 more are under current consideration at the Food and Drug Administration following successful phase III clinical programs. However, before feeling triumphant, we must recognize that our current therapies ...